Cutaneous T-cell lymphoma in Kuwait: a retrospective analysis of treatment modalities and prognostic factors

Authors:

Abstract
Background Cutaneous T-cell lymphoma (CTCL) is a rare malignancy with limited data available from the Middle East. This study evaluated the clinical characteristics, treatment patterns, and outcomes of CTCL patients treated in Kuwait. Methods This was a retrospective review of all adult patients diagnosed between February 2021 and March 2024. Data included demographics, staging, treatment modalities, and outcomes. Kaplan–Meier analysis was used to evaluate progression-free survival (PFS) and overall survival (OS). Results The study included 86 patients. The mean age at diagnosis was 44 years (range: 16–80), and 84% of patients presented with early-stage disease (IA–IIA). NB-UVB phototherapy was the most common treatment for early-stage disease, while brentuximab vedotin was frequently used for advanced diseases. Median OS was 30 months in patients with advanced disease and not reached in those with early-stage disease (p = 0.003). Median PFS was 22 months overall, and significantly longer in early-stage than advanced disease (50 vs. 15 months, p = 0.009). Advanced stage, blood involvement, and elevated LDH were significant predictors of worse PFS. Conclusion This study provides the first real-world analysis of CTCL outcomes in Kuwait. The findings underscore the importance of early detection and the role of novel therapies in disease management.

This publication has 18 references indexed in Scilit: